PE20100740A1 - Formulacion farmaceutica de rapida disolucion que comprende clorhidrato de vardenafil trihidrato - Google Patents

Formulacion farmaceutica de rapida disolucion que comprende clorhidrato de vardenafil trihidrato

Info

Publication number
PE20100740A1
PE20100740A1 PE2010000018A PE2010000018A PE20100740A1 PE 20100740 A1 PE20100740 A1 PE 20100740A1 PE 2010000018 A PE2010000018 A PE 2010000018A PE 2010000018 A PE2010000018 A PE 2010000018A PE 20100740 A1 PE20100740 A1 PE 20100740A1
Authority
PE
Peru
Prior art keywords
pharmaceutical formulation
quick
vardenafil
formulation including
dissolving pharmaceutical
Prior art date
Application number
PE2010000018A
Other languages
English (en)
Inventor
Peter Serno
Roland Heinig
Kerstin Pauli
Yutaka Hayauchi
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36264023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100740(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20100740A1 publication Critical patent/PE20100740A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UNA FORMULACION FARMACEUTICA QUE CONTIENE CLORHIDRATO DE VARDENAFILO TRIHIDRATADO, CARACTERIZADA PORQUE SE DISUELVE AL MENOS EL 80% DE LA DOSIS DE VARDENAFILO EN LA FORMA DE SUSTANCIA. DICHA SAL DE VARDENAFILO ESTA MICRONIZADA CON UN TAMANO DE PARTICULA INFERIOR A 20um O ESTA EN FORMA DE TIERRA, AMORFA O DISULTA. LA COMPOSICION FARMACEUTICA CONTIENE ADEMAS DE 40-99% DE ALCOHOLES DE AZUCARES SELECCIONADO DE MANITOL O SORBITOL
PE2010000018A 2005-03-01 2006-02-28 Formulacion farmaceutica de rapida disolucion que comprende clorhidrato de vardenafil trihidrato PE20100740A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005009240A DE102005009240A1 (de) 2005-03-01 2005-03-01 Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften

Publications (1)

Publication Number Publication Date
PE20100740A1 true PE20100740A1 (es) 2010-10-28

Family

ID=36264023

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000230A PE20061015A1 (es) 2005-03-01 2006-02-28 Formas farmaceuticas con propiedades farmacocineticas mejoradas
PE2010000018A PE20100740A1 (es) 2005-03-01 2006-02-28 Formulacion farmaceutica de rapida disolucion que comprende clorhidrato de vardenafil trihidrato

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000230A PE20061015A1 (es) 2005-03-01 2006-02-28 Formas farmaceuticas con propiedades farmacocineticas mejoradas

Country Status (39)

Country Link
US (2) US8613950B2 (es)
EP (2) EP1858490B1 (es)
JP (1) JP5122984B2 (es)
KR (1) KR101360526B1 (es)
CN (2) CN101141950B (es)
AR (2) AR053552A1 (es)
AT (1) ATE552828T1 (es)
AU (1) AU2006220100B2 (es)
BR (1) BRPI0609375A2 (es)
CA (1) CA2599617C (es)
CR (2) CR9339A (es)
CY (1) CY1112874T1 (es)
DE (1) DE102005009240A1 (es)
DK (1) DK1858490T3 (es)
DO (1) DOP2006000049A (es)
ES (1) ES2384109T3 (es)
GT (1) GT200600097A (es)
HK (1) HK1118457A1 (es)
HN (1) HN2006009000A (es)
HR (1) HRP20120545T1 (es)
IL (2) IL185552A (es)
MA (1) MA29376B1 (es)
MX (1) MX2007010527A (es)
MY (2) MY177386A (es)
NO (2) NO332368B1 (es)
NZ (1) NZ561004A (es)
PE (2) PE20061015A1 (es)
PL (1) PL1858490T3 (es)
PT (1) PT1858490E (es)
RS (1) RS52374B (es)
RU (2) RU2423970C2 (es)
SG (1) SG160330A1 (es)
SI (1) SI1858490T1 (es)
TN (1) TNSN07336A1 (es)
TW (1) TWI387465B (es)
UA (1) UA93200C2 (es)
UY (1) UY29395A1 (es)
WO (1) WO2006092207A1 (es)
ZA (1) ZA200707320B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
FR2906140B1 (fr) * 2006-09-22 2008-12-05 Philippe Perovitch Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
DE102009020888A1 (de) * 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
ES2604307T3 (es) 2009-05-20 2017-03-06 Sumitomo Dainippon Pharma Co., Ltd. Comprimido de disgregación oral revestido por vía seca
GB2497728A (en) 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
CN103372014B (zh) * 2012-04-26 2015-10-21 齐鲁制药有限公司 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法
CN102727455B (zh) * 2012-07-03 2016-06-29 北京科信必成医药科技发展有限公司 一种他达那非口腔崩解片及其制备方法
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN110193015A (zh) * 2018-02-27 2019-09-03 广州朗圣药业有限公司 一种盐酸伐地那非口腔崩解片及其制备方法
CN108272765B (zh) * 2018-04-26 2021-02-02 江西杏林白马药业股份有限公司 含盐酸伐地那非的药物组合物、口崩片及其制备、应用
BR112020021852A2 (pt) 2018-05-02 2021-02-23 Ferring B.V. formulações farmacêuticas aperfeiçoadas
CN110840851A (zh) * 2019-08-16 2020-02-28 天津仁卫生物医药科技有限公司 一种盐酸伐地那非口腔崩解片及其制备方法
IT201900020350A1 (it) 2019-11-05 2021-05-05 Alpex Pharma Sa Formulazione orodispersibile di vardenafil
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114848603B (zh) * 2022-04-25 2023-12-12 湖北菲瑞生物药业有限公司 一种伐地那非冻干闪释片及其制备工艺

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
GB790762A (en) 1953-08-28 1958-02-19 Arthur Poole A hydrate of lignocaine hydrochloride and process for making it
CH367510A (de) * 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1051734A (es) * 1963-01-16
GB1042471A (en) * 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
DE3166627D1 (en) * 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
US4939544A (en) * 1989-11-01 1990-07-03 Eastman Kodak Company Mask for radiation emitting panel
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
EP0524180B1 (en) * 1990-04-11 1995-04-26 The Upjohn Company Taste masking of ibuprofen by fluid bed coating
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
EP0669324A4 (en) 1993-09-10 1996-04-03 Eisai Co Ltd CHINAZOLIN DERIVATIVES.
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CN100430396C (zh) * 1997-11-12 2008-11-05 拜耳医药保健股份公司 用作磷酸二酯酶抑制剂的2-苯基取代的咪唑并三嗪酮
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US6743443B1 (en) * 1998-10-05 2004-06-01 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
US6284270B1 (en) * 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
TWI224966B (en) 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
CA2395548A1 (en) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Imidazo 1,3,5 triazinones and the use thereof
US6774128B2 (en) * 2000-04-19 2004-08-10 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
AU2001278673A1 (en) * 2000-10-30 2002-05-15 Lupin Limited Rapidly disintegrating sustained release cefuroxime axetil composition
CN100372536C (zh) * 2001-02-15 2008-03-05 田边三菱制药株式会社 在口腔中迅速崩解的片剂
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
WO2002089808A1 (de) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Neue verwendung von 2-phenyl-substituierten imidazotriazinonen
PL361452A1 (en) 2001-07-27 2004-10-04 Yamanouchi Pharmaceutical Co.Ltd. Compositions containing sustained-release fine grains for tablets quickly disintegrable in the oral cavity and process for producing the same
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
GB0219516D0 (en) 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
KR101125268B1 (ko) 2003-06-06 2012-04-23 에띠팜 구강 분산성 다중층 정제
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
RU2388466C2 (ru) 2004-04-27 2010-05-10 Медисинова, Инк. Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006058250A2 (en) 2004-11-24 2006-06-01 Spi Pharma, Inc. Orally disintegrating compositions
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
EP1898879A1 (en) 2005-06-23 2008-03-19 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
JP5074190B2 (ja) 2005-09-02 2012-11-14 富士化学工業株式会社 口腔内速崩壊性錠剤

Also Published As

Publication number Publication date
MY148698A (en) 2013-05-31
MX2007010527A (es) 2007-11-08
CA2599617A1 (en) 2006-09-08
WO2006092207A1 (de) 2006-09-08
MY177386A (en) 2020-09-14
NO332368B1 (no) 2012-09-03
HK1118457A1 (en) 2009-02-13
PT1858490E (pt) 2012-06-19
CN102198140A (zh) 2011-09-28
ATE552828T1 (de) 2012-04-15
DK1858490T3 (da) 2012-07-23
UY29395A1 (es) 2006-10-02
PL1858490T3 (pl) 2012-09-28
US8613950B2 (en) 2013-12-24
AU2006220100B2 (en) 2011-08-18
CY1112874T1 (el) 2016-04-13
HRP20120545T1 (hr) 2012-07-31
BRPI0609375A2 (pt) 2010-03-30
JP5122984B2 (ja) 2013-01-16
KR101360526B1 (ko) 2014-02-21
DE102005009240A1 (de) 2006-09-07
RU2481110C2 (ru) 2013-05-10
AR111572A2 (es) 2019-07-31
CA2599617C (en) 2012-01-10
RS52374B (en) 2012-12-31
CR9339A (es) 2007-12-17
NZ561004A (en) 2010-12-24
ZA200707320B (en) 2009-08-26
SI1858490T1 (sl) 2012-07-31
IL246548A0 (en) 2016-08-31
AU2006220100A1 (en) 2006-09-08
US20080249096A1 (en) 2008-10-09
IL185552A0 (en) 2008-01-06
UA93200C2 (ru) 2011-01-25
CR20130381A (es) 2013-09-12
ES2384109T3 (es) 2012-06-29
JP2008531614A (ja) 2008-08-14
TWI387465B (zh) 2013-03-01
NO20074848L (no) 2007-09-27
TNSN07336A1 (en) 2008-12-31
EP2377523A1 (de) 2011-10-19
TW200640503A (en) 2006-12-01
EP1858490B1 (de) 2012-04-11
NO344546B1 (no) 2020-01-27
RU2011111106A (ru) 2012-09-27
HN2006009000A (es) 2010-08-05
RU2423970C2 (ru) 2011-07-20
IL185552A (en) 2017-06-29
DOP2006000049A (es) 2006-10-31
NO20120203L (no) 2007-09-27
MA29376B1 (fr) 2008-04-01
KR20070110109A (ko) 2007-11-15
AR053552A1 (es) 2007-05-09
PE20061015A1 (es) 2006-10-20
RU2007135982A (ru) 2009-04-10
CN101141950B (zh) 2011-06-08
SG160330A1 (en) 2010-04-29
US20140186444A1 (en) 2014-07-03
EP1858490A1 (de) 2007-11-28
CN102198140B (zh) 2016-06-08
CN101141950A (zh) 2008-03-12
GT200600097A (es) 2006-11-13

Similar Documents

Publication Publication Date Title
PE20100740A1 (es) Formulacion farmaceutica de rapida disolucion que comprende clorhidrato de vardenafil trihidrato
ES2551307T3 (es) Composición de inhalación que contiene aclidinio para tratamiento de enfermedad pulmonar obstructiva crónica
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
AR095441A1 (es) Formulaciones farmacéuticas resistentes a la adulteración, proceso de preparación, método
CL2009000228A1 (es) Compuestos derivados de 7,8-dihidropirido[4,3-d]pirimidin con un sustituyente oximico, inhibidores de hsp90; y composicion farmaceutica que comprene a dichos compuestos.
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
PE20070583A1 (es) Formulacion que comprende un inhibidor de dipeptidil-peptidasa iv y metformina
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
PE20070192A1 (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
PE20071220A1 (es) Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona y su proceso de preparacion
AR077629A1 (es) Mimetico de smac
CO6220927A2 (es) Comprimido farmaceutico que comprende telmisartan y sorbitol
PE20150676A1 (es) Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
CO6241104A2 (es) "composiciones farmaceuticas que comprende {4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil}-5-cloro-tiofen-2-il-sulfonilurea o sales de la misma para la inhibicion de la agregacion de plaquetas inducidas por adp"
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
PE20081891A1 (es) Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
CR20160293A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
AR076864A1 (es) Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.

Legal Events

Date Code Title Description
FC Refusal